Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHaleon plc

Haleon plc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
9.07 USD 0.10 ( 1.11%)
Last update at 2026-11-10T17:58:00Z
VOLUME
10062016
Market Cap
37492.40M
P/E
23.88

Momentum Score

…

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.97
Low
9.07
High
52 Week Price Range
7.39
Low
9.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Haleon plc is a global consumer healthcare company selling a diversified portfolio of over‑the‑counter and oral‑health products in developed and emerging markets. Long‑term growth may be supported by aging populations, greater self‑care and e‑commerce adoption, and scale that could support steady cash flows. Investors may find the company attractive for its brand depth and exposure to resilient consumer demand.

Key risks include intense competition from OTC and private‑label products, regulatory and safety scrutiny, supply‑chain and currency volatility, and execution risk in sustaining innovation.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.97
Dividend Yield
1.13%
Revenue TTM
11314.00M
Revenue Per Share
2.46
Gross Profit TTM
6737.00M
Debt / Equity
0.64
ROE
5.99%
Net Debt
9756.00M
ROCE
5.99%
Diluted EPS TTM
0.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax 1618.00M 1636.00M 1591.00M 886.00M
Minority interest -59.00M -49.00M -36.00M -32.00M
Net income 1060.00M 1390.00M 1145.00M 655.00M
Selling general administrative 4483.00M 4086.00M 4220.00M 3596.00M
Gross profit 6577.00M 5950.00M 5910.00M 4802.00M
Reconciled depreciation 287.00M 268.00M 305.00M 260.00M
Ebit 1825.00M 1638.00M 1598.00M 897.00M
Ebitda 2163.00M 1951.00M 1905.00M 1176.00M
Depreciation and amortization 338.00M 313.00M 307.00M 279.00M
Operating income 1825.00M 1638.00M 1598.00M 897.00M
Other operating expenses 9033.00M 7907.00M 8294.00M 7583.00M
Interest expense 258.00M 12.00M 15.00M 26.00M
Tax provision 499.00M 197.00M 410.00M 199.00M
Interest income 51.00M 17.00M 18.00M 24.00M
Net interest income -207.00M -2.00M -9.00M -10.00M
Income tax expense 499.00M 197.00M 410.00M 199.00M
Total revenue 10858.00M 9545.00M 9892.00M 8480.00M
Total operating expenses 4752.00M 4312.00M 4312.00M 3905.00M
Cost of revenue 4281.00M 3595.00M 3982.00M 3678.00M
Total other income expense net -207.00M -2.00M -7.00M -11.00M
Net income from continuing ops 1119.00M 1439.00M 1181.00M 687.00M
Net income applicable to common shares 1060.00M 1390.00M 1145.00M 655.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 34815.00M 34451.00M 34130.00M 35711.00M
Intangible assets 20040.00M 18949.00M 18953.00M 19841.00M
Other current assets 2027.00M 61.00M 135.00M 266.00M
Total liab 18358.00M 7971.00M 7907.00M 8299.00M
Total stockholder equity 16331.00M 26355.00M 26112.00M 27321.00M
Other current liab 312.00M 1954.00M 2281.00M 2540.00M
Common stock 92.00M 1.00M 1.00M 1.00M
Capital stock 92.00M 1.00M 1.00M 1.00M
Retained earnings 26730.00M 37986.00M 37763.00M 5106.00M
Other liab 3810.00M 3645.00M 3788.00M 3909.00M
Good will 8396.00M 8246.00M 8265.00M 8171.00M
Other assets 421.00M 343.00M 302.00M 267.00M
Cash 684.00M 414.00M 334.00M 340.00M
Cash and equivalents 684.00M 1.00M 1.00M 1.00M
Total current liabilities 4370.00M 4238.00M 4014.00M 4269.00M
Current deferred revenue - 11.00M 11.00M 7.00M
Net debt 9756.00M 577.00M 153.00M 302.00M
Short term debt 437.00M 904.00M 382.00M 521.00M
Short long term debt 437.00M 874.00M 348.00M 481.00M
Short long term debt total 10440.00M 991.00M 487.00M 642.00M
Other stockholder equity -10491.00M -11632.00M -11652.00M 20842.00M
Property plant equipment 1899.00M 1662.00M 1602.00M 1621.00M
Total current assets 4059.00M 5251.00M 5008.00M 5811.00M
Net tangible assets -12105.00M -840.00M -1106.00M -691.00M
Short term investments - 1.00M 1.00M 1.00M
Net receivables 1881.00M 3825.00M 3590.00M 3994.00M
Long term debt 10003.00M - - -
Inventory 1348.00M 951.00M 949.00M 1211.00M
Accounts payable 3621.00M 1369.00M 1340.00M 1201.00M
Accumulated other comprehensive income - -11632.00M -11652.00M 1372.00M
Non currrent assets other 201.00M 8.00M 10.00M 10.00M
Non current assets total 30756.00M 29200.00M 29122.00M 29900.00M
Capital lease obligations 161.00M 117.00M 139.00M 161.00M
Long term debt total 10003.00M 87.00M 105.00M 121.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -8784.00M 100.00M 158.00M 219.00M
Change to liabilities 387.00M 41.00M 140.00M -256.00M
Total cashflows from investing activities -8784.00M -33.00M 1030.00M 291.00M
Net borrowings 9441.00M -30.00M -16.00M -41.00M
Total cash from financing activities 6911.00M -1236.00M -2437.00M -925.00M
Change to operating activities 171.00M -190.00M -273.00M -380.00M
Net income 1119.00M 1439.00M 1181.00M 687.00M
Change in cash 205.00M 82.00M -6.00M 138.00M
Begin period cash flow 406.00M 323.00M 329.00M 191.00M
End period cash flow 611.00M 405.00M 323.00M 329.00M
Total cash from operating activities 2063.00M 1356.00M 1407.00M 786.00M
Depreciation 287.00M 268.00M 305.00M 260.00M
Other cashflows from investing activities -8456.00M 16.00M 19.00M 24.00M
Dividends paid -2682.00M -1148.00M -2371.00M -1152.00M
Change to inventory -292.00M -17.00M 130.00M 232.00M
Change to account receivables -85.00M 14.00M 18.00M -57.00M
Other cashflows from financing activities 11111.00M -88.00M -56.00M 227.00M
Change to netincome 535.00M -150.00M -58.00M 332.00M
Capital expenditures 328.00M 298.00M 318.00M 243.00M
Change in working capital 181.00M -152.00M 15.00M -461.00M
Stock based compensation - -376.00M -702.00M -261.00M
Other non cash items 476.00M -20.00M 198.00M 362.00M
Free cash flow 1735.00M 1058.00M 1089.00M 543.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HLN
Haleon plc		 0.10
1.11%		 9.07 23.88 16.78 3.31 1.80 4.00 20.87
MKKGY
Merck KGaA ADR		 -0.25
0.74%		 33.46 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 0.40
0.24%		 170.10 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.31
1.47%		 20.78 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 42.77 - 10.66 0.01 1.16 2.94 23.11

Profile*

Haleon plc

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands includes Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Weybridge, the United Kingdom.

Building 5, Weybridge, United Kingdom, KT13 0NY

44 1932 822000

https://www.haleon.com

24622

Name Title Year Born
Mr. Brian McNamara CEO & Exec. Director 1967
Mr. Tobias Hestler CFO & Exec. Director 1972
Ms. Amy Landucci Head of Digital and Technology NA
Mr. Bjarne Philip Tellmann Gen. Counsel 1967
Ms. Tamara Rogers Chief Marketing Officer 1969
Ms. Mairead Nayager Chief HR Officer 1975
Mr. Bart Derde Head of Quality and Supply Chain 1969
Mr. Filippo Lanzi Head of EMEA & LatAm NA
Ms. Teri Lyng Head of Transformation & Sustainability 1962
Ms. Jooyong Lee Head of Strategy and Office of the CEO 1977

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PET
CAD 22.84
+6.13%
QTWO
CAD 1.70
+5.59%
CHR
CAD 34.77
+5.59%
IFOS
CAD 1.77
+4.73%
GUD
CAD 12.02
+3.62%
MUX
CAD 18.68
-18.21%
URE
CAD 0.97
-14.16%
WELL
CAD 3.73
-12.24%
SGML
CAD 7.47
-10.54%
ISO
CAD 11.43
-10.14%

Equity Sectors*

  • Basic Materials

    -4.26%

  • Communication Services

    +0.36%

  • Consumer Cyclical

    -0.62%

  • Consumer Defensive

    -0.33%

  • Energy

    -0.09%

  • Financial Services

    -0.18%

  • Healthcare

    -1.69%

  • Industrials

    -1.10%

  • Real Estate

    -0.83%

  • Technology

    -0.67%

  • Utilities

    +0.31%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…